Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Return on Sales (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Return on Sales data on record, last reported at 39.66% in Q3 2025.

  • For Q3 2025, Return on Sales fell 8204.0% year-over-year to 39.66%; the TTM value through Sep 2025 reached 39.66%, down 8204.0%, while the annual FY2024 figure was 55.04%, N/A changed from the prior year.
  • Return on Sales reached 39.66% in Q3 2025 per RANI's latest filing, up from 43.67% in the prior quarter.
  • Across five years, Return on Sales topped out at 179.96% in Q4 2022 and bottomed at 74.06% in Q1 2025.
  • Average Return on Sales over 5 years is 6.3%, with a median of 4.02% recorded in 2023.
  • Peak YoY movement for Return on Sales: soared 19950bps in 2022, then tumbled -16911bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 19.54% in 2021, then surged by 1021bps to 179.96% in 2022, then tumbled by -94bps to 10.84% in 2023, then crashed by -241bps to 15.29% in 2024, then tumbled by -159bps to 39.66% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 39.66% in Q3 2025, 43.67% in Q2 2025, and 74.06% in Q1 2025.